{
  "report_rows": [
    {
      "kpi": "Adj. EPS (operating)",
      "prediction": "BEAT",
      "answer": "pred ~$1.93 vs. cons $1.838",
      "confidence": "HIGH"
    },
    {
      "kpi": "Total Revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$6.05B vs. cons $6.100B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Biotech Segment Organic Growth",
      "prediction": "BEAT",
      "answer": "pred ~+6.5% vs. cons ~+5.5%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 Adj. EPS (FY 2026)",
      "prediction": "BETTER",
      "answer": "guide ~$8.55-$8.65 vs. cons midpoint $8.45",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY 2026 Core Revenue (FY 2026)",
      "prediction": "UNCHANGED",
      "answer": "guide 3-6% maintained vs. current guide 3-6%",
      "confidence": "HIGH"
    },
    {
      "kpi": "Bioprocessing Equipment Tone (Qualitative, FY 2026)",
      "prediction": "BETTER",
      "answer": "guide upgrade from flat to modestly positive vs. current flat assumption",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 3.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 5.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 out-period math pulls H2 estimates up; short-cover bid; bioprocessing equipment narrative takes days to be reflected in models",
  "day5_confidence": "MEDIUM"
}